IN2012DN06279A - - Google Patents

Info

Publication number
IN2012DN06279A
IN2012DN06279A IN6279DEN2012A IN2012DN06279A IN 2012DN06279 A IN2012DN06279 A IN 2012DN06279A IN 6279DEN2012 A IN6279DEN2012 A IN 6279DEN2012A IN 2012DN06279 A IN2012DN06279 A IN 2012DN06279A
Authority
IN
India
Prior art keywords
rosacea
receptor
cxcl5
chemokines
interleukin
Prior art date
Application number
Inventor
Jérôme Aubert
Martin Steinhoff
Michel Rivier
Johannes Voegel
Original Assignee
Galderma Res & Dev
Uni Munster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Uni Munster filed Critical Galderma Res & Dev
Publication of IN2012DN06279A publication Critical patent/IN2012DN06279A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to markers for rosacea among the chemokines and cytokines and their receptors chosen from interleukin 8 (IL 8) CXCL1 CXCL2 CXCL3 and CXCL5 the CXCR1 receptor and the CXCR2 receptor and also to a method for the diagnosis of rosacea.
IN6279DEN2012 2009-12-17 2010-12-16 IN2012DN06279A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28211309P 2009-12-17 2009-12-17
PCT/EP2010/069896 WO2011073321A1 (en) 2009-12-17 2010-12-16 Markers and method for the diagnosis of rosacea

Publications (1)

Publication Number Publication Date
IN2012DN06279A true IN2012DN06279A (en) 2015-09-25

Family

ID=43417037

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6279DEN2012 IN2012DN06279A (en) 2009-12-17 2010-12-16

Country Status (12)

Country Link
US (1) US20130017969A1 (en)
EP (1) EP2513328A1 (en)
JP (1) JP2013514070A (en)
KR (1) KR20120115321A (en)
CN (1) CN102762742A (en)
AU (1) AU2010332876A1 (en)
BR (1) BR112012014678A2 (en)
CA (1) CA2783693A1 (en)
IN (1) IN2012DN06279A (en)
MX (1) MX2012006623A (en)
RU (1) RU2012130069A (en)
WO (1) WO2011073321A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000871A1 (en) * 2011-06-27 2013-01-03 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
EP2723892A2 (en) * 2011-06-27 2014-04-30 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
EP2771484A1 (en) * 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2791354B1 (en) 2011-12-16 2017-06-14 Galderma Research & Development Method for the diagnosis of rosacea
US9860241B2 (en) * 2014-04-15 2018-01-02 Level 3 Communications, Llc Device registration, authentication, and authorization system and method
KR101712747B1 (en) 2015-11-06 2017-03-07 가톨릭대학교 산학협력단 Composition for preventing or treating skin disease comprising eupatilin
CN106119348B (en) * 2016-06-27 2018-02-23 中南大学湘雅医院 A kind of myasthenia gravis detection kit and application for non-coding lnc CXCL1 and encoding gene cxcl1 being combined as detecting or diagnosing screening marker
KR102216941B1 (en) * 2020-08-12 2021-02-18 주식회사 큐티스의생명연구센터 Minimally invasive kit evaluating rosacea type sensitive skin including microneedle patch and biomarker for evaluating rosacea type sensitive skin
EP4194565A4 (en) * 2020-08-10 2024-05-22 Cutis Biomedical Res Center Minimally invasive kit for diagnosing skin condition, comprising microneedle patch
CN113462770B (en) * 2021-08-25 2023-03-31 中国医科大学附属第一医院 Chemotactic factor as molecular marker for diagnosing rosacea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118141A1 (en) * 2005-05-04 2009-05-07 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of ocular rosacea
EP2124058B1 (en) * 2006-01-05 2014-03-05 Galderma Research & Development Acne diagnostic method by using lesions biomarkers and in vitro screening method for identifying modulators thereof
EP2069377A4 (en) * 2006-09-27 2009-11-11 Univ California Methods and compositions for the treatment of skin diseases and disorders
EP2212442A1 (en) * 2007-10-26 2010-08-04 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
FR2923610B1 (en) 2007-11-14 2009-11-27 Galderma Res & Dev NON-INVASIVE METHOD OF COLLECTING BIOLOGICAL DATA FOR THE ESTABLISHMENT OF DIAGNOSIS OF SKIN PATHOLOGY.

Also Published As

Publication number Publication date
US20130017969A1 (en) 2013-01-17
KR20120115321A (en) 2012-10-17
MX2012006623A (en) 2012-11-30
CN102762742A (en) 2012-10-31
EP2513328A1 (en) 2012-10-24
JP2013514070A (en) 2013-04-25
RU2012130069A (en) 2014-01-27
BR112012014678A2 (en) 2016-04-05
CA2783693A1 (en) 2011-06-23
AU2010332876A1 (en) 2012-07-12
WO2011073321A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
IN2012DN06279A (en)
MX2010003139A (en) Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient.
MX2019013922A (en) Novel inhibitors of map4k1.
ECSP11010932A (en) AZAINDAZOL COMPOUNDS AS AN RECRUITOR OF THE RECEIVER OF CCR1
EA201171074A1 (en) CYTOTOXIC CONJUGATES WITH CONNECTION, BINDING THE NEUROPEPTIDE Y RECEPTOR
EA200970051A1 (en) ANTAGONIST RECEPTOR IL-8
ECSP11011433A (en) FENILURES AND PHENILAMIDS REPLACED AS LIGANDS OF THE VANILLOID RECEIVER
CR10379A (en) PHARMACEUTICAL COMPOSIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40.
EA201201541A1 (en) NEW CYCLOGEXYLAMINE DERIVATIVES THAT HAVE AN AGONISTIC ACTIVITY WITH RESPECT TO β2 ADRENERGIC RECEPTOR AND ANTAGONISTIC ACTIVITY WITH RESPECT TO THE M3 MUSCARRUM IG.
BRPI1014956B8 (en) anti-inflammatory agents
EA201290940A1 (en) NEW CONNECTIONS AS SELECTIVE ANTAGONISTS OF NK3 RECEPTOR, PHARMACEUTICAL COMPOSITION AND METHODS OF THEIR USE FOR DAMAGE MEDIATED BY NK3 RECEPTORS
EP2592156A3 (en) Gene expression markers of tumor resistance to HER2 inhibitor treatment
CL2014001452A1 (en) Compounds derived from dihydro-benzo-oxacin and dihydro-pyrido-oxacin; pharmaceutical composition; method to modulate the activity of pi3k enzymes; method for treatment; and use for the treatment of rheumatoid arthritis, pemphigus vulgaris, multiple sclerosis, myasthenia gravis, allergy and malaria, among other diseases.
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
SG154441A1 (en) Treatment of demyelinating disorders
WO2010044543A3 (en) Heterocyclic compound as protein kinase inhibitor
WO2010112458A8 (en) Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
WO2012103360A3 (en) Wnt compositions and methods of use thereof
MX2010006089A (en) Methods of treating copd.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EP3384937A3 (en) Bisphosphonate-prodrugs
WO2007015157A3 (en) Mc4r-ag0nists for the treatment of urinary tract dysfunction
WO2012078053A8 (en) Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
MA32943B1 (en) Biperiden spiro-pyrrolidone and biperidenone are substituted, prepared and used in treatment
UA102231C2 (en) Using fipronil for increasing wheat yield and a method for treating wheat